16 HOW SUPPLIED/STORAGE AND HANDLING

It works to improve moderate to adverse health issues. Take sildenafil citrate 100mg orally with a glass of water. One can consume the dosage once within a 24-hour duration. Avoid consumption of alcohol and grapefruit beverage with the medicine as it might cause adverse health issues.

Frequently asked questions

Others were reported to have occurred hours to days after the use of sildenafil and sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors [ Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil.

Revatio Injection

Try not to consume the medicine with oily or high-fat meal. A person taking nitroglycerin should avoid the use of medicine. Do not take the medicine if you are having local treatment medicines for improving ED. Consult a doctor before medicine use if you have or had cardiovascular issues, high or low blood pressure problem, bleeding disorder, kidney and liver issues or genital deformity.

Sildigra 25mg Tablet Sildigra 50mg Tablet Sildigra 75mg Tablet Sildigra 100mg Tablet Sildigra 120mg Tablet Sildigra 250mg Tablet Sildigra 225mg Tablet Sildigra Gold 200mg Tablet Silagra Super power 160mg Tablet Silagra Soft Chewable Tablet Sildigra Professional 100mg Tablet Sildigra Black Force 200mg Tablet Sildigra XL Plus 150mg Tablet It is a prescription medicine and requires proper medical attention while on medication. The regular regimen is required while on medication. Avoid overdose of the medicine as it might cause adverse health effects.

2. Revatio

It works to improve moderate to adverse health issues. Take sildenafil citrate 100mg orally with a glass of water. One can consume the dosage once within a 24-hour duration. Avoid consumption of alcohol and grapefruit beverage with the medicine as it might cause adverse health issues. Try not to consume the medicine with oily or high-fat meal.

More common

A person taking nitroglycerin should avoid the use of medicine. Do not take the medicine if you are having local treatment medicines for improving ED. Consult a doctor before medicine use if you have or had cardiovascular issues, high or low blood pressure problem, bleeding disorder, kidney and liver issues or genital deformity. Sildigra 25mg Tablet Sildigra 50mg Tablet Sildigra 75mg Tablet Sildigra 100mg Tablet Sildigra 120mg Tablet Sildigra 250mg Tablet Sildigra 225mg Tablet Sildigra Gold 200mg Tablet Silagra Super power 160mg Tablet Silagra Soft Chewable Tablet Sildigra Professional 100mg Tablet Sildigra Black Force 200mg Tablet Sildigra XL Plus 150mg Tablet It is a prescription medicine and requires proper medical attention while on medication. The regular regimen is required while on medication.

Corresponding author

Avoid overdose of the medicine as it might cause adverse health effects. Some side effects of Sildenafil citrate 100mg (Sildigra 100 ) The medicine is an effective and well-tolerated but might cause severe issues when overdosed. It might cause a headache, dizziness, facial flushing, indigestion. It is highly advisable to consult a doctor before medicinal use. •For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Some side effects of Sildenafil citrate 100mg (Sildigra 100 ) The medicine is an effective and well-tolerated but might cause severe issues when overdosed. It might cause a headache, dizziness, facial flushing, indigestion. It is highly advisable to consult a doctor before medicinal use. •For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity (2.1) •Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg (2.1) •Maximum recommended dosing frequency is once per day (2.1) Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg.

• Men should not take sildenafil LP 100 mg if they have severe heart problems.
• Use caution if you have low blood pressure or a history of strokes.
• Always inform your doctor about current medications before use.

When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at 25 mg [ The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels sildenafil 100 mg cost of sildenafil by 11-fold [ Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold [ Sildenafil tablets 25 mg USP is supplied as Pale blue to blue, round film-coated tablets, debossed with “25” on one side and “SL” on other side. •Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. Sildenafil tablets was shown to potentiate the hypotensive effect of nitrates (4.1,7.1,12.2) •Known hypersensitivity to sildenafil or any component of tablet (4.2) •Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3) After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [ •Patients should not use sildenafil if sexual activity is inadvisable due to cardiovascular status (5.1) •Patients should seek emergency treatment if an erection lasts >4 hours.

5.1 Mortality with Pediatric Use

There are no controlled clinical data on the safety or efficacy of sildenafil in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution. PDE5 inhibitors, including sildenafil, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [ Consideration should be given to the following: •Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. •In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see].Dosage and Administration (2.3) •In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. •Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs.

Who should not take sildenafil?

Sildenafil has systemic vasodilatory properties and may further lower blood pressure in patients taking anti-‑hypertensive medications. In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and sildenafil, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted [ The safety of sildenafil is unknown in patients with bleeding disorders and patients with active peptic ulceration. •Cardiovascular [see]Warnings and Precautions (5.1) •Prolonged Erection and Priapism [see]Warnings and Precautions (5.2) •Effects on the Eye [see]Warnings and Precautions (5.3) •Hearing Loss [see]Warnings and Precautions (5.4) •Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [see]Warnings and Precautions (5.5) •Adverse Reactions with the Concomitant Use of Ritonavir [see]Warnings and Precautions (5.6) •Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see]Warnings and Precautions (5.7) •Effects on Bleeding [see]Warnings and Precautions (5.8) •Counseling Patients About Sexually Transmitted Diseases [see]Warnings and Precautions (5.9) Sildenafil was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide. In placebo-controlled clinical studies, the discontinuation rate due to white sildenafil tablets adverse reactions for sildenafil (2.5%) was not significantly different from placebo (2.3%). The type of adverse reactions in flexible-dose studies, which reflect the recommended dosage regimen, was similar to that for fixed- dose studies.

How should I store sildenafil?

† Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. The following events occurred in <2% of patients in controlled clinical trials; a causal relationship to sildenafil is uncertain. Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful: Analysis of the safety database from controlled clinical trials showed no apparent difference in adverse reactions in patients taking sildenafil with and without anti-hypertensive medication. Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of sildenafil. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity. Use sildenafil with caution in patients predisposed to priapism (5.2) •Patients should stop sildenafil tablets and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Patients with a "crowded" optic disc may also be at an increased risk of NAION. •Patients should stop sildenafil tablets and seek prompt medical attention sildenafil citrate 200mg price in the event of sudden decrease or loss of hearing (5.4) •Caution is advised when sildenafil is co-administered with alpha-blockers or anti-hypertensives. Concomitant use may lead to hypotension (5.5) •Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. Decrease in sildenafil dosage is recommended (2.4,5.6) Sildenafil has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg), [ Use with caution in patients with the following underlying conditions which can be particularly sensitive to the actions of vasodilators including sildenafil - those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure. There are no controlled clinical data on the safety or efficacy of sildenafil in the following groups; if prescribed, this should be done with caution. •Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; •Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg); •Patients with cardiac failure or coronary artery disease causing unstable angina. Sildenafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).

5.7 Combination with other PDE-5 inhibitors

However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity (2.1) •Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg (2.1) •Maximum recommended dosing frequency is once per day (2.1) Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at 25 mg [ The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels sildenafil 100 mg cost of sildenafil by 11-fold [ Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold [ Sildenafil tablets 25 mg USP is supplied as Pale blue to blue, round film-coated tablets, debossed with “25” on one side and “SL” on other side. •Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. Sildenafil tablets was shown to potentiate the hypotensive effect of nitrates (4.1,7.1,12.2) •Known hypersensitivity to sildenafil or any component of tablet (4.2) •Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3) After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered.

Sildenafil Oral Film for ED

Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [ •Patients should not use sildenafil if sexual activity is inadvisable due to cardiovascular status (5.1) •Patients should seek emergency treatment if an erection lasts >4 hours. Use sildenafil with caution in patients predisposed to priapism (5.2) •Patients should stop sildenafil tablets and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Patients with a "crowded" optic disc may also be at an increased risk of NAION. •Patients should stop sildenafil tablets and seek prompt medical attention sildenafil citrate 200mg price in the event of sudden decrease or loss of hearing (5.4) •Caution is advised when sildenafil is co-administered with alpha-blockers or anti-hypertensives. Concomitant use may lead to hypotension (5.5) •Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures.

Similar content being viewed by others

Decrease in sildenafil dosage is recommended (2.4,5.6) Sildenafil has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg), [ Use with caution in patients with the following underlying conditions which can be particularly sensitive to the actions of vasodilators including sildenafil - those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure. There are no controlled clinical data on the safety or efficacy of sildenafil in the following groups; if prescribed, this should be done with caution. •Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; •Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg); •Patients with cardiac failure or coronary artery disease causing unstable angina. Sildenafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). However, there are no controlled clinical data on the safety or efficacy of sildenafil in patients with sickle cell or related anemias. However, there are no controlled clinical data on the safety or efficacy of sildenafil in patients with sickle cell or related anemias. There are no controlled clinical data on the safety or efficacy of sildenafil in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution. PDE5 inhibitors, including sildenafil, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [ Consideration should be given to the following: •Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.

•In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see].Dosage and Administration (2.3) •In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose.

•Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs. Sildenafil has systemic vasodilatory properties and may further lower blood pressure in patients taking anti-‑hypertensive medications.

8.7 Hepatic Impairment

In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and sildenafil, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted [ The safety of sildenafil is unknown in patients with bleeding disorders and patients with active peptic ulceration. •Cardiovascular [see]Warnings and Precautions (5.1) •Prolonged Erection and Priapism [see]Warnings and Precautions (5.2) •Effects on the Eye [see]Warnings and Precautions (5.3) •Hearing Loss [see]Warnings and Precautions (5.4) •Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [see]Warnings and Precautions (5.5) •Adverse Reactions with the Concomitant Use of Ritonavir [see]Warnings and Precautions (5.6) •Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see]Warnings and Precautions (5.7) •Effects on Bleeding [see]Warnings and Precautions (5.8) •Counseling Patients About Sexually Transmitted Diseases [see]Warnings and Precautions (5.9) Sildenafil was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide.

In placebo-controlled clinical studies, the discontinuation rate due to white sildenafil tablets adverse reactions for sildenafil (2.5%) was not significantly different from placebo (2.3%). The type of adverse reactions in flexible-dose studies, which reflect the recommended dosage regimen, was similar to that for fixed- dose studies. † Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. The following events occurred in <2% of patients in controlled clinical trials; a causal relationship to sildenafil is uncertain. Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful: Analysis of the safety database from controlled clinical trials showed no apparent difference in adverse reactions in patients taking sildenafil with and without anti-hypertensive medication. Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of sildenafil. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity.

• Sildenafil LP 100 mg should be taken on an empty stomach for best absorption.
• Avoid drinking alcohol while using sildenafil tablets LP 100 mg.
• Store tablets in a cool, dry place away from children.

Others were reported to have occurred hours to days after the use of sildenafil and sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors [ Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil.